| Outcome Measures: |
Primary: Incidence of Adverse events., All visits or at occurrence.|Clinical safety lab tests., Weeks 12, 24, and Final Visit.|12-lead electrocardiogram., Weeks: 24 and Final Visit.|Urinalysis., Weeks: 12, 24, 36, 48 and Final Visit.|Change from Baseline in Blood pressure and pulse., At all visits.|Change from Baseline in Body weight., At all visits.|Left ventricular mass index by body surface area measured by echocardiogram., Weeks: 24 and Final Visit. | Secondary: Change from Baseline in total daily dose of insulin., At all visits.|Change from Baseline in triglycerides., Weeks: 24 and Final Visit.|Change from Baseline in cholesterol., Weeks 24 and Final Visit|Change from Baseline in total, high-density lipoproteins., Weeks: 24 and Final Visit.|Change from Baseline in low-density lipoproteins., Weeks 24 and Final Visit|Change from Baseline in low-density lipoprotein fractionation., Weeks 24 and Final Visit|Change from Baseline in very low-density lipoprotein., Weeks 24 and Final Visit|Change from Baseline in free fatty acids., Weeks 24 and Final Visit|Change from Baseline in apolipoproteins (AI, B)., Weeks 24 and Final Visit
|
